Article
Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders
Public Deposited
- Creator
- Abstract
- Fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability and autism spectrum disorder. Loss of the fragile X mental retardation protein, FMRP, engenders molecular, behavioral, and cognitive deficits in FXS patients. Experiments using different animal models advanced our knowledge of the pathophysiology of FXS and led to the discovery of many targets for drug treatments. In this review, we discuss the potential of metformin, an antidiabetic drug approved by the US Food and Drug Administration, to correct core symptoms of FXS and other neurological disorders in humans. We summarize its mechanisms of action in different animal and cellular models and human diseases.
English
- Last modified
- 2023-04-12
- Subject
- Publisher
- Language
- Identifier
- Source
- Rights
- Posted with permission from the Annual Review of Medicine, Volume 70, © by Annual Reviews, https://www.annualreviews.org.
- Department
- Faculty
- Type
- Date
- Bibliographic citation
- Gantois I, Popic J, Khoutorsky A, Sonenberg N. Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders. Annu Rev Med. 2019 Jan 27;70:167-181. doi: 10.1146/annurev-med-081117-041238. Epub 2018 Oct 26. PMID: 30365357
- Status
- Published